To evaluate the cardiovascular risk in cancer survivors and assess the effectiveness of existing risk prediction tools, emphasizing the need for improved tools.
Key Findings:
SCORE2 underestimated cardiovascular risk in cancer patients, particularly in females (E/O ratio 0.63) and males (E/O ratio 0.91), with implications for clinical practice.
Recalibration improved SCORE2's performance, with a C-statistic of 0.693 post-recalibration, indicating moderate discrimination power.
Sensitivity analyses indicated improved performance of SCORE2 over time since cancer diagnosis, suggesting the need for ongoing assessment.
Interpretation:
The study confirms that conventional CV risk prediction tools underestimate risk in cancer survivors and suggests recalibration as a potential improvement method, with implications for clinical application.
Limitations:
The study is hypothesis-generating and not ready for clinical application, which limits immediate use.
C-statistic of 0.693 indicates only moderate discrimination power, affecting the reliability of predictions.
Recalibration needs validation in larger, independent cohorts to ensure generalizability.
Conclusion:
While recalibration of existing tools shows promise, further research is needed to establish clinical significance and validate findings across diverse cancer populations, emphasizing the importance of this validation.
